Skip to main content

Table 2 (abstract A59). Components of SLEDAI Present within 30 days of Baseline Visit and at Most Recent Follow Up Visits

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

SLEDAI Component

Baseline Visit, n=380

n (%)

Most Recent

Follow Up Visit , n=219

n (%)

Seizure

0

0

Psychosis

4 (1%)

0

Organic Brain Syndrome

0

0

Visual Disturbance

4 (1%)

2 (1%)

Cranial Nerve Disorder

0

0

Lupus Headache

11 (3%)

4 (2%)

Cerebrovascular Accident

0

0

Vasculitis

11 (3%)

7 (3%)

Arthritis

61 (16%)

46 (12%)

Myositis

15 (4%)

7 (3%)

Urinary Casts

57 (15%)

18 (8%)

Hematuria

27 (7%)

11 (5%)

Proteinuria

27 (7%)

7 (3%)

Pyuria

23 (6%)

7 (3%)

Rash

80 (21%)

33 (15%)

Alopecia

27 (7%)

7 (3%)

Mucosal Ulcers

30 (8%)

7 (3%)

Pleurisy

4 (1%)

0

Pericarditis

4 (1%)

0

Low Complement

148 (39%)

68 (31%)

Increased DNA Binding

103 (27%)

50 (23%)

Fever

27 (7%)

2 (1%)

Thrombocytopenia

15 (4%)

2 (1%)

Leukopenia

53 (14%)

22 (10%)

  1. IRB approval was via Protocol 00054616 (Duke University)